These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8791029)

  • 1. Evaluation of the long-term safety and efficacy of 311C90 in the treatment of migraine.
    Geraud GE
    Eur Neurol; 1996; 36 Suppl 2():24-7. PubMed ID: 8791029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 311C90: long-term efficacy and tolerability profile for the acute treatment of migraine. International 311C90 Long-Term Study Group.
    Zagami AS
    Neurology; 1997 Mar; 48(3 Suppl 3):S25-8. PubMed ID: 9071267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can oral 311C90, a novel 5-HT1D agonist, prevent migraine headache when taken during an aura?
    Dowson A
    Eur Neurol; 1996; 36 Suppl 2():28-31. PubMed ID: 8791030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study.
    Visser WH; Klein KB; Cox RC; Jones D; Ferrari MD
    Neurology; 1996 Feb; 46(2):522-6. PubMed ID: 8614525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period.
    Thomsen LL; Dixon R; Lassen LH; Gibbens M; Langemark M; Bendtsen L; Daugaard D; Olesen J
    Cephalalgia; 1996 Jun; 16(4):270-5. PubMed ID: 8792040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical effectiveness of 311C90 in the acute treatment of migraine.
    Ferrari MD
    Eur Neurol; 1996; 36 Suppl 2():4-7. PubMed ID: 8791025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists.
    Ferrari MD
    Neurology; 1997 Mar; 48(3 Suppl 3):S21-4. PubMed ID: 9071266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical applications of zolmitriptan (Zomig, 311C90).
    Lipton RB; Stewart WF
    Cephalalgia; 1997 Oct; 17 Suppl 18():53-9. PubMed ID: 9399017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group.
    Headache; 1998 Mar; 38(3):173-83. PubMed ID: 9563207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical safety of 311C90: aggregated data from patients and volunteers to date.
    Earl NL
    Eur Neurol; 1996; 36 Suppl 2():8-12. PubMed ID: 8791026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers.
    Seaber E; On N; Phillips S; Churchus R; Posner J; Rolan P
    Br J Clin Pharmacol; 1996 Feb; 41(2):141-7. PubMed ID: 8838441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan.
    Edmeads JG; Millson DS
    Cephalalgia; 1997 Oct; 17 Suppl 18():41-52. PubMed ID: 9399016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy.
    Schoenen J; Sawyer J
    Cephalalgia; 1997 Oct; 17 Suppl 18():28-40. PubMed ID: 9399015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging preclinical and clinical profile of 311C90: a poster review and discussion.
    Ferrari MD
    Eur Neurol; 1996; 36 Suppl 2():19-23. PubMed ID: 8791028
    [No Abstract]   [Full Text] [Related]  

  • 15. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group.
    Rapoport AM; Ramadan NM; Adelman JU; Mathew NT; Elkind AH; Kudrow DB; Earl NL
    Neurology; 1997 Nov; 49(5):1210-8. PubMed ID: 9371896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 311C90: patient profiles and typical case histories of migraine management.
    Dowson AJ
    Neurology; 1997 Mar; 48(3 Suppl 3):S29-33. PubMed ID: 9071268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache.
    Mauskop A; Farkkila M; Hering-Hanit R; Rapoport A; Warner J
    Curr Med Res Opin; 1999; 15(4):282-9. PubMed ID: 10640260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90).
    Rolan P
    Cephalalgia; 1997 Oct; 17 Suppl 18():21-7. PubMed ID: 9399014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group.
    Solomon GD; Cady RK; Klapper JA; Earl NL; Saper JR; Ramadan NM
    Neurology; 1997 Nov; 49(5):1219-25. PubMed ID: 9371897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the trigemino-vascular system with 5-HT1D agonist drugs: selectively targeting additional sites of action.
    Martin GR
    Eur Neurol; 1996; 36 Suppl 2():13-8. PubMed ID: 8791027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.